Status:
COMPLETED
ATX Study:A Study of Avastin (Bevacizumab), Tarceva (Erlotinib) and Xeloda (Capecitabine) in Patients With Locally Advanced and/or Metastatic Pancreatic Cancer
Lead Sponsor:
Hoffmann-La Roche
Conditions:
Pancreatic Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
This 2 part study will evaluate the safety and efficacy of a combination of Avastin, Tarceva and Xeloda (ATX) as second-line treatment in patients with locally advanced and/or metastatic pancreatic ca...
Eligibility Criteria
Inclusion
- adult patients, \>=18 years of age;
- pancreatic cancer with locally advanced and/or metastatic disease (stage IV);
- chemonaive for metastatic or locally advanced disease;
- ECOG performance status of 0-2.
Exclusion
- local (stage IA to IIB)and locally advanced (stage III) pancreatic cancer;
- previous exposure to Avastin, Tarceva or Xeloda;
- other primary tumor within the last 5 years prior to enrollment, except for adequately treated cancer in situ of cervix, or basal cell skin cancer;
- current or recent chronic use of aspirin (\>325 mg/day) or full therapeutic dose of anticoagulants or thrombolytic agents.
Key Trial Info
Start Date :
January 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2013
Estimated Enrollment :
32 Patients enrolled
Trial Details
Trial ID
NCT00925769
Start Date
January 1 2009
End Date
December 1 2013
Last Update
August 7 2015
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Vienna, Austria, 1100
2
Vienna, Austria, 1130